Document is current
Any future updates will be listed below
-
Authors
Loo, Suet Kee
Sica, Gabriel
Wang, Xian
Li, Tingting
Chen, Luping
Gaither-Davis, Autumn
Huang, Yufei
Burns, Timothy F.
Stabile, Laura P.
Gao, Shou-Jiang
-
Funding
Funding for this research was provided by:
National Institute of Health (CA096512, CA124332, CA278812, CA284554)
- License Information
-
More Information
Article History
Received: 21 August 2024
Accepted: 25 September 2024
First Online: 9 October 2024
Declarations
:
: This retrospective study was approved by the Institutional Review Board of the University of Pittsburgh (Protocol ID: STUDY22020142) and informed consent from patients were obtained in accordance with the Declaration of Helsinki.
: Not applicable.
: Gabriel Sica reports ownership of stocks of Johnson and Johnson, and Abbvie. T Timothy F. Burns reports a grant from Novartis, consulting fees from Blueprint Medicines, Mirati Therapeutics, EMD Serono, Janssen Scientific Affairs, Jazz Pharmaceuticals, Amgen, AstraZeneca, Takeda and Eli Lilly, Inc, honoraria from Amgen Mexico, participation on a Data Safety Monitoring Board of Advarra, Inc (Lantern Pharma) during the conduct of the study. Shou-Jiang Gao reports receipt of honoraria from Wiley. The remaining authors declare no conflict of interest.
